We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
- Authors
Shah, Neil P; Kantarjian, Hagop M; Kim, Dong-Wook; Réa, Delphine; Dorlhiac-Llacer, Pedro E; Milone, Jorge H; Vela-Ojeda, Jorge; Silver, Richard T; Khoury, H Jean; Charbonnier, Aude; Khoroshko, Nina; Paquette, Ronald L; Deininger, Michael; Collins, Robert H; Otero, Irma; Hughes, Timothy; Bleickardt, Eric; Strauss, Lewis; Francis, Stephen; Hochhaus, Andreas
- Abstract
Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with dasatinib 70 mg twice daily in chronic-phase (CP) chronic myelogenous leukemia (CML) after imatinib treatment failure. In phase I, responses occurred with once-daily administration despite only intermittent BCR-ABL inhibition. Once-daily treatment resulted in less toxicity, suggesting that toxicity results from continuous inhibition of unintended targets. Here, a dose- and schedule-optimization study is reported.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 19, p3204
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.14.9260